Novo Nordisk A/S : Status regarding Novo Nordisk's holding of its own shares (31 March 2016)

company announcement

Status regarding Novo Nordisk's holding of its own shares (31 March 2016)

Bagsværd, Denmark, 01 April 2016 - In continuation of the company's announcements dated 29 October 2015 and 3 February 2016 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2016 owned 58,672,645 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 11,734,529 or 2.3% of the total share capital.

In the first quarter of 2016 a total of 10,670,964 B shares were repurchased, and 4,167,022 B shares were disposed to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information

Media:
Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
Investors:
Peter Hugreffe Ankersen	+45 3075 9085	phak@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Kasper Veje	+45 3079 8519	kpvj@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet: www.novonordisk.com CVR no:

24 25 67 90

Company announcement No 26 / 2016